Echocardiographic evaluation of patients with primary antiphospholipid syndrome

American Heart Journal

Volumn 137, Issue 5, 1999, Pages 973-978

  Espínola Zavaleta, Nilda ^b   Vargas Barrón, Jesús ^a   Colmenares Galvis, Terry ^b   Cruz Cruz, Flory ^b   Romero Cárdenas, Angel ^b   Keirns, Candace ^b   Amigo, Mary Carmen ^b  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; WARFARIN;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL ARTICLE; FEMALE; HEART ATRIUM SEPTUM DEFECT; HEART INFARCTION; HEART LEFT VENTRICLE WALL MOTION; HUMAN; MALE; PRIORITY JOURNAL; THROMBOSIS; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; VALVULAR HEART DISEASE;

EID: 0032929793     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70424-2     Document Type: Article

References (16)

1. 1. Hughes GRV. The antiphospholipid syndrome. Lancet 1993;342:341-4.
2. 2. Galve E, Ordi J, Barquinero J, et al. Valvular heart disease in the primary antiphospholipid syndrome Ann Intern Med 1992;166:293-8.
3. 3. Kaplan S, Chartash EK, Pizzarello RA, et al. Cardiac manifestations of the anti-phospholipid syndrome. Am Heart J 1992;124:1331-8.
4. 4. García-Torres R, Amigo MC, De la Rosa A, et al. Valvular heart disease in primary antiphospholipid syndrome (PAPS): clinical and morphological findings. Lupus 1996;5:56-61.
5. 5. Brenner B, Blumfeld Z, Markiewicz W, et al. Cardiac involvement in patients with primary antiphospholipid syndrome. J Am Coll Cardiol 1991;181:931-6.
6. 6. Jafar MZ, Chester-Morgan M, Gorcsan J III, et al. Transesophageal echocardiographic detection of multiple mitral valve masses in primary antiphospholipid syndrome with stroke. Am Heart J 1994;127:445-6.
7. 7. Skyrme-Jones A, Wardrop CA, Wiles CM, et al. Transesophageal echocardiographic demonstration of resolution of mitral vegetations after warfarin in a patient with the primary antiphospholipid syndrome. J Am Soc Echocardiogr 1995;8:251-6.
8. 2 glycoprotein 1 but negative antiphospholipid antibodies. Am J Med 1996; 101:472-81.
9. 9. Roldan CA, Shively BK, Lau CC, et al. Systemic lupus erythematosus valve disease by transesophageal echocardiography and the role of antiphospholipid antibodies. J Am Coll Cardiol 1992;20:1127-34.
10. 10. Samaritano LR, Gharavi AE, Lockshin MD. Antiphospholipid antibody syndrome: immunologic and clinical aspects. Semin Arthritis Rheum 1990;20:81-96.
11. 11. Nihoyannopoulos P, Gomez PM, Joshi J, et al. Cardiac abnormalities in systemic lupus erythematosus: association with raised anticardiolipin antibodies. Circulation 1990;82:369-75.
12. 12. Hasselaar P, Derkson RHWM, Oosting JD, et al. Synergistic effect of low doses of tumor necrosis factor and sera from patients with systemic lupus erythematosus on the expression of procoagulant activity by cultured cells. Thromb Haemost 1989; 62:654-60.
13. 13. Libman E, Sacks B. A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med 1924;33:701-37.
14. 14. Hamstein A, Norberg R, Bjokholm M, et al. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1986;1:113-6.
15. 15. Carreras LO, Vermylen JG. "Lupus" anticoagulant and thrombosis; possible role of inhibition of prostacyclin formation. Thromb Haemost 1982;48:38-40.
16. 16. Hojnik M, George J, Ziporen L, et al. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 1996;93:1579-87.